-
Product Insights
Hemophilia A (Factor VIII Deficiency) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemophilia A (Factor VIII Deficiency) - Drugs In Development, 2023’, provides an overview of the Hemophilia A (Factor VIII Deficiency) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemophilia A (Factor VIII Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
MPS I (Mucopolysaccharidosis I) is an inherited lysosomal storage disorder caused by a deficiency of alpha-L-iduronidase, a lysosomal enzyme normally required for the breakdown of certain complex carbohydrates known as glycosaminoglycans (GAGs). Symptoms include abnormal bones in the spine, claw hand, cloudy corneas, deafness and heart valve problems. Treatment includes bone marrow transplantation, enzyme therapy and gene therapy. The Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Pipeline market research report provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis I...
-
Product Insights
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a condition that affects many different parts of the body and occurs almost exclusively in males. Signs and symptoms include claw-like hands, protruding tongue, changing facial features, including thickening of the lips, tongue and nostrils and delayed development. Treatment includes bone marrow transplantation, enzyme therapy and gene therapy. The Mucopolysaccharidosis type II (MPS II) (Hunter Syndrome) pipeline market research report  provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis...
-
Product Insights
Hemophilia B (Factor IX Deficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Its treatment includes replacing the defective clotting factor. The Hemophilia B pipeline market research report provides comprehensive information on the therapeutics under development for Hemophilia B, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and...